Neutral endopeptidase 24.11 loss in metastatic human prostate cancer contributes to androgen-independent progression

Nature Medicine

Volumn 4, Issue 1, 1998, Pages 50-57

  Papandreou, Christos N ^a,b   Usmani, Badar ^a   Geng, Yiping ^a   Bogenrieder, Thomas ^a   Freeman, Ronald ^a   Wilk, Sherwin ^c   Finstad, Connie L ^a   Reuter, Victor E ^a   Powell, C Thomas ^a   Scheinberg, David ^a   Magill, Catherine ^d   Scher, Howard L ^b   Albino, Anthony P ^e   Nanus, David M ^a,b,f  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

^c CITY UNIVERSITY OF NEW YORK   (United States)

^d Arris Pharmaceuticals   (United States)

^e AMERICAN HEALTH FOUNDATION   (United States)

^f WEILL CORNELL MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MEMBRANE METALLOENDOPEPTIDASE;

ARTICLE; CARCINOGENESIS; ENZYME ACTIVITY; ENZYME DEFICIENCY; HUMAN; HUMAN CELL; MALE; METASTASIS POTENTIAL; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN DEGRADATION;

BIOPSY; CELL DIVISION; CELL NUCLEUS; DIHYDROTESTOSTERONE; DISEASE PROGRESSION; GENE TRANSFER TECHNIQUES; HUMANS; KINETICS; MALE; NEOPLASM METASTASIS; NEPRILYSIN; POLYMERASE CHAIN REACTION; PROSTATIC NEOPLASMS; RECOMBINANT PROTEINS; TETRACYCLINE; TIME FACTORS; TRANSFECTION; TUMOR CELLS, CULTURED; TUMOR MARKERS, BIOLOGICAL;

EID: 0031889217     PISSN: 10788956     EISSN: None     Source Type: Journal    
DOI: 10.1038/nm0198-050     Document Type: Article

References (48)

1. Bologna, M., Festuccia, C., Muzi, P., Biordi, L. & Gomel, M. Bombesin stimulates growth of human prostatic cells in vitro. Cancer 63, 1714-1720 (1989).
2. Sehgal, I., et al. Neurotensin is an autocrine trophic factor stimulated by androgen withdrawal in human prostate cancer. Proc. Natl. Acad. Sci. USA 91, 4673-4677 (1994).
3. Nelson, J.B., et al. Endothelin-1 production and decreased endothelin B receptor expression in advanced prostate cancer. Cancer Res. 56, 663-668 (1996).
4. Abrahamsson, P.A. & Di Sant'Agnese, P.A. Neuroendocrine cells in the human prostate gland. J. Androl. 14, 307-309 (1993).
5. Nelson, J.B., et al. Identification of endothelin-1 in the pathophysiology of metastatic adenocarcinoma of the prostate. Nature Med. 1, 944-949 (1995).
6. Cussenot, O., et al. Plasma neuroendocrine markers in patients with benign prostatic hyperplasia and prostatic carcinoma. J. Urol. 155, 1340-1343 (1996).
7. 4) bombesin by tumor cells. Prostate 25, 29-38 (1994).
8. Pinski, J., Halmos, G. & Schally, A.V. Somatostatin analog RC-160 and bombesin/gasthn-releasing peptide antagonist RC-3095 inhibit the growth of androgen-independent DU-145 human prostate cancer cell line in nude mice. Cancer Lett. 71, 189-196 (1993).
9. Aprikian, A.C., et al. Neuroendocrine differentiation in metastatic prostatic adenocarcinoma. J. Urol. 151, 914-919 (1994).
10. Cohen, R., Glezerson, O. & Haffejee, Z. Neuro-endocrine cells: Prognostic parameter in prostate cancer. Br. J. Urol. 68, 57-62 (1991).
11. Kenny, A.J., O'Hare, M. J. & Custerson, B.A. Cell-surface peptidases as modulators of growth and differentiation. Lancet 2, 785-787 (1989).
12. Shipp, M.A. & Look, A.T. Hematopoietic differentiation antigens that are membrane-associated enzymes: Cutting is the key! Blood 84, 1052-1070 (1993).
13. Shipp, M.A., et al. Common acute lymphoblastic leukemia antigen (CALLA) is active neutral endopeptidase 24.11 ("enkephalinase"): direct evidence by cDNA transfection analysis. Proc. Natl. Acad. Sci. USA 86, 297-301 (1989).
14. Checler, F., Emson, P.C., Vincent, J.P. & Kitabgi, P. Inactivation of neurotensin by rat brain synaptic membranes: Cleavage at the Pro10-Tyr11 bond by endopeptidase 24.11 (enkephalinase) and a peptidase different from proline-endopeptidase. J. Neurochem. 43, 1295-1301 (1984).
15. Kenny, A.J. Endopeptidase-24.11 : putative substrates and possible roles. Biochem Soc. Trans. 21, 663-668 (1993).
16. Shipp, M.A., et at. CDIO/neutral endopeptidase 24.11 hydrolyzes bombesin-like peptides and regulates the growth of small cell carcinomas of the lung. Proc. Natl. Acad. Sci. USA 88, 10662-10666 (1991).
17. Nanus, D.M., Papandreou, C.N. & Albino, A.P. Cell-Surface Peptidases in Health and Disease (eds. Kenny, J. & Boustead, CM.) 353-369 (BIOS Scientific Publishers, Oxford, 1997).
18. Fournie-Zaluski, M.C., et al. Inhibitory potency of various peptides on enkephalinase activity from mouse striatum. Biochem. Biophys. Res. Commun. 91, 130-135 (1979).
19. Matsas, R., Kenny, A.J. & Turner, A.J. The metabolism of neuropeptides: The hydrolysis of peptides, including enkephalins, tacykinins and their analogues, by endopeptidase-24.11. Biochem J. 223, 433-440 (1984).
20. Cschwend, J.E., Fair, W.R. St Powell, C.T. Evaluation of the tetracycline-repressible transactivator system for inducible gene expression in human prostate cancer cell lines. Prostate 33, 166-176 (1997).
21. Gossen, M. & Bujard, H. Tight control of gene expression in mammalian cells by tetracycline-responsive promoters. Proc. Natl. Acad. Sci. USA 89, 5547-5551 (1992).
22. Veldscholte, J., Berrevoets, C.A., Brinkmann, A.O., Grootegoed, J.A. & Mulder, E. Anti-androgens and the mutated androgen receptor of LNCaP cells: Differential effects on binding affinity, heat-shock protein interaction, and transcription activation. Biochemistry 31, 2393-2399 (1992).
23. Klocker, H., et al. Basic Research in Urologic Oncology (eds. Luciani, L., Debruyne, F.M.J. & Schalken, J.A.) 28-40 (Karger, Basel, 1996).
24. Taplin, M.E., et al. Mutation of the androgen-receptor gene in metastatic androgen-independent prostate cancer. N. Engl. J. Med. 332, 1393-1398 (1995).
25. Ishimaru, F. & Shipp, M.A. Analysis of the human CDIO/neutral endopeptidase 24.11 promoter region: Two separate regulatory elements. Blood 85, 3199-3207 (1995).
26. Israeli, R.S., Powell, C.T., Corr, J.G., Fair, W.R. & Heston, W.D. Expression of the prostate-specific membrane antigen. Cancer Res. 54, 1807-1811 (1994).
27. Borson, D.B. & Gruenert, D.C. Clucocorticoids induce neutral endopeptidase in transformed human tracheal epithelial cells. Am. J. Physiol. 260, L83-L89 (1991).
28. Casey, M.L., Smith, J.W., Nagai, K., Hersh, L.B. & MacDonald, P.C. Progesterone-regulated cyclic modulation of membrane metalloendopeptidase (enkephalinase) in human endometrium. J. Biol. Chem. 34, 23041-23047 (1991).
29. Scher, H.I., Mazumdar, M. & Kelly, W.K. Clinical trials in relapsed prostate cancer: Defining the target. J. Natl. Cancer Inst. 88, 1623-1634 (1997).
30. McDonnell, T.J., et al. Expression of the proto-oncogene bcl-2 in the prostate and its association with emergence of androgen-independent prostate cancer. Cancer Res. 52, 6940-6944 (1992).
31. Bookstein, R., MacGrogan, D., Hilsenbeck, S.G., Sharkey, F. & Allred, D.C. p53 is mutated in a subset of advanced-stage prostate cancers. Cancer Res. 53, 3369-3373 (1993).
32. Steiner, M.S. Review of peptide growth factors in benign prostatic hyperplasia and urological malignancy.). Urol. 153, 1085-1096 (1995).
33. Duncan, M.D., Harmon, J.W. & Duncan, K.L.K. Actin disruption inhibits bombesin stimulation of focal adhesion kinase (pp125(FAK)) in prostate carcinoma. J. Surg. Res. 63, 359-363 (1996).
34. Rozengurt, E. Convergent signalling in the action of integrins, neuropeptides, growth factors and oncogenes. Cancer Surv. 24, 81-96 (1995).
35. Frame, K.L., Patton, K., Reed, M.J., Ghilchik, M.W. & Parish, D.C. Angiotensin-converting enzyme and enkephalinase in human breast cyst fluid. Br. J. Cancer 74, 807-813 (1996).
36. Bogenrieder, T., et al. Expression and localization of aminopeptidase A, aminopeptidase N, and dipeptidyl peptidase IV in benign and malignant human prostate tissue. Prostate 33, 225-232 (1997).
37. Papandreou, C.N., Bogenrieder, T., Scher, H.I., Albino, A.P. & Nanus, D.M. Expression and sequence analysis of the SD11/WAF1/CIP1/p21 tumor suppressor gene in prostate cancer cell lines. Int. J. Oncol. 8, 1237-1241 (1996).
38. Orlowski, M., Mtchaud, C. & Chu, T. G. A soluble metalloendopeptidase from rat brain. Purification of the enzyme and determination of specificity with synthetic and natural peptides. Eur. J. Biochem. 135, 81-88 (1983).
39. Nanus, D.M., et al. Transformation of human kidney proximal tubule cells by ras-containing retroviruses: Implications for tumor progression. J. Exp. Med. 169, 953-972 (1989).
40. Hoffman, A.D., et al. Expression of retinoic acid receptor beta in human renal cell carcinomas correlates with sensitivity to the antiproliferative effect of 13-cis retinoic acid. Clin. Cancer Res. 2, 1077-1082 (1996).
41. Nabeya, Y., et al. The mutational status of p53 protein in gastric and esophageal adenocarcinoma cell lines predicts sensitivity to chemotherapeutic agents. Int. J. Cancer 64, 1-10 (1995).
42. Cohen, A.J., et al. Neutral endopeptidase variable expression in human lung, inactivation in lung cancer, and modulation of peptide induced calcium flux. Cancer Res. 56, 831-839 (1996).
43. Nanus, D.M., et al. Flow cytometry as a predictive indicator in patients with operable gastric cancer. J. Clin. Oncol. 7, 1105-1112 (1989).
44. Nanus, D.M., et al. Molecular cloning of the human kidney differentiation antigen gp160: Human aminopeptidase A. Proc. Natl. Acad. Sci. USA 90, 7069-7073 (1993).
45. Greenberg, M.E. & Bender, T.P. Identification of newly transcribed RNA. Current Protocols in Molecular Biology (eds. Ausubel, F.M., et al.) 4.10.1-4.10.4 (Wiley Interscience, Boston, 1993).
46. D'Adamio, L, Shipp, M.A., Masteller, E.L. & Reinherz, E.L. Organization of the gene encoding common acute lymphoblastic leukemia antigen (neutral endopeptidase 24.11): multiple miniexons and separate 5' untranslated regions. Proc Natl. Acad. Sci. USA 86, 7103-7107 (1989).
47. Nanus, D.M., et al. Expression of basic fibroblast growth factor in primary human renal tumors: Correlation with poor survival. J. Natl. Cancer Inst. 85, 1597-1599 (1993).
48. Sunday, M.E., Hua, J., Torday, J.S., Reyer, B. & Shipp, M.A. CD/10 neutral endopeptidase 24.11 in developing human fetal lung. J. Clin. Invest. 90, 2517-2525 (1992).